Cardiovascular Sciences, Inc. Reaches Operating Agreement With Medical Technologies Enterprises, Inc.
March 25 2008 - 8:10AM
Marketwired
ORLANDO, FL , a client company of the award-winning University
of Central Florida Technology Incubator program, is enthused to
announce that the company has reached an operating agreement with
Med. Tech. Enterprises, Inc. Under this agreement, Cardiovascular
Sciences, Inc. will immediately assume all daily operations of Med.
Tech. Enterprises, Inc. Under this agreement, earnings will accrue
to the benefit of Cardiovascular Sciences, Inc.
Cardiovascular Sciences, Inc. is already well underway in
developing and producing a proprietary line of health-related
products. Mr. Eric Edelmann, president of Med. Tech. Enterprises,
stated, "With all the recent advances and impressive data that have
become available on nutritionals, supplements and anti-oxidants, it
is appropriate and even exciting to team up with a company like
Cardiovascular Sciences to bring our own product line of quality
and effective health products to market."
The Company's CEO, Dr. Larry Hooper, expressed, "This is a very
positive step forward for Cardiovascular Sciences and its
shareholders. At the same time, we will continue to develop our
primary, post-surgical anti-adhesion technology which stands to
propel Cardiovascular Sciences as a leading innovator in medical
technology."
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions.
Adhesions and the complications of adhesions are a significant
problem worldwide for a wide range of specialists, including
general surgeons, cardiothoracic surgeons, orthopedic, plastic, and
ophthalmologic and otolaryngology specialists to name just some of
them. In addition, the veterinary field has a tremendous need for a
product that can prevent similar problems in a wide variety of
animals. The Company's unique materials and processes promise a
more cost-effective and decidedly more efficient and capable means
to deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida
(UCF) and previously at other institutions indicate that The
Company is on the right path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters, cell
engineered vascular tissues, and a method for improved recovery of
the heart following cardioplegia. This yields a diversified
portfolio with projects in various stages of development.
www.cvsciences.org
Forward-looking statements in this release are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
certain risks, and uncertainties and actual results could differ
from those discussed. This material is information only and is not
an offer or solicitation to buy or sell the securities.
For more information contact: Cardiovascular Sciences Investor
Relations 800-858-7502 ir@cvsciences.org
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Apr 2024 to May 2024
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From May 2023 to May 2024
